Robert Jr. Leasure Buys 6,000 Shares of Bioanalytical Systems, Inc. (NASDAQ:BASI) Stock

Bioanalytical Systems, Inc. (NASDAQ:BASI) insider Robert Jr. Leasure acquired 6,000 shares of the business’s stock in a transaction on Friday, June 7th. The shares were purchased at an average cost of $1.96 per share, for a total transaction of $11,760.00. Following the completion of the transaction, the insider now owns 100,615 shares in the company, valued at approximately $197,205.40. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Robert Jr. Leasure also recently made the following trade(s):

  • On Tuesday, March 12th, Robert Jr. Leasure acquired 6,000 shares of Bioanalytical Systems stock. The shares were purchased at an average cost of $1.94 per share, for a total transaction of $11,640.00.

Bioanalytical Systems stock opened at $1.98 on Wednesday. The company has a current ratio of 0.63, a quick ratio of 0.54 and a debt-to-equity ratio of 0.91. Bioanalytical Systems, Inc. has a fifty-two week low of $1.18 and a fifty-two week high of $2.59.

Bioanalytical Systems (NASDAQ:BASI) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $9.34 million for the quarter. Bioanalytical Systems had a negative net margin of 2.82% and a negative return on equity of 3.12%.

A hedge fund recently raised its stake in Bioanalytical Systems stock. Renaissance Technologies LLC raised its position in shares of Bioanalytical Systems, Inc. (NASDAQ:BASI) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 234,881 shares of the company’s stock after acquiring an additional 19,600 shares during the quarter. Renaissance Technologies LLC owned approximately 2.28% of Bioanalytical Systems worth $486,000 at the end of the most recent quarter. 6.02% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at

About Bioanalytical Systems

Bioanalytical Systems, Inc provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products.

Recommended Story: Dividend Yield

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with's FREE daily email newsletter.